

In re application of



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JAN 19 2001

Lu et al.

Appl. No.: 09/499526

Group Art Unit: Not Yet Assigned

TECH CENTER 1600/2900

Filed: February 10, 2000

Examiner: Not Yet Assigned

For: Methods and Reagents for Treating Glucose

Metabolic Disorders

### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C.

20231 on October 17, 2000.

Robert King

## **Customer Corrections Branch**

Assistant Commissioner for Patents Washington, DC 20231

Sir:

# REQUEST FOR CORRECTION OF FILING RECEIPT

Enclosed is a copy of the Filing Receipt received from the United States Patent and Trademark Office for the above-referenced application. There is an error on the Filing Receipt, which is marked in red on the copy. The first invertor's name and residence are incorrectly listed. The correct name and residence are:

Kuanghui Lu, Brookline, MA.

The second inventor's residence is also incorrectly listed. The correct residence is:

Kevin Pang, Belmont, MA.

Applicants respectfully request issuance of a corrected filing receipt for this application

If there are any questions concerning this request, the Examiner can contact the undersigned at (617) 832-1242.

Respectfully submitted, FOLEY, HOAG & ELIOT LLP

October 17, 2000

Anita Varma Reg. No. 43,221

Patent Group Foley, Hoag & Eliot LLP One Post Office Square Boston, MA 02109-2170





JAN 19 2001



# United States Patent and Trademark Office

UNITED STATES PARENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

www.uspto.gov

APPLICATION NUMBER 09/499,526

FILING DATE 02/10/2000 **GRP ART UNIT** 1642

2676

FIL FEE REC'D ATTY.DOCKET.NO ONV.058.01

DRAWINGS 12

TOT CLAIMS 50

IND CLAIMS

Patent Group Foley Hoag & Eliot LLP One Post Office Square Boston, MA 02109-2170



**FILING RECEIPT** 

\*OC00000005437674\*

Date Mailed: 09/29/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any c rrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply t the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) Kvanghui Brookline

Huang-hui Lu, Gambridge, MA; Kevin Pang, Cambridge, MA; Belmon+

Continuing Data as Claimed by Applicant

THIS APPLN CLAIMS BENEFIT OF 60/119,577 02/10/1999

**Foreign Applications** 

If Required, Foreign Filing License Granted 04/19/2000

RECEIVED

OCT 0 5 2000

**Title** 

Methods and reagents for treating glucose metabolic disorders

PATENT DEPT. DOCKETING

**Preliminary Class** 

530

Data entry by : HARDY, EUGENIA

Team: OIPE

Date: 09/29/2000

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15



#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN CENTER 1500129 FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in fall applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

# PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231